1 – 13 of 13
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Coronary Artery Lesion Lipid Content and Plaque Burden in Diabetic and Nondiabetic Patients : PROSPECT II
(
- Contribution to journal › Article
-
Mark
Clinical trials to improve outcomes in patients with elevated Lp(a) undergoing PCI : The time has arrived
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
Dual antithrombotic treatment in chronic coronary syndrome : European Society of Cardiology criteria vs. CHADS-P2A2RC score
(
- Contribution to journal › Article
-
Mark
Temporal trends in characteristics and outcome of heart failure patients with and without significant coronary artery disease
(
- Contribution to journal › Article
-
Mark
On the Natural History of Coronary Artery Disease : A Longitudinal Nationwide Serial Angiography Study
(
- Contribution to journal › Article
- 2021
-
Mark
Appropriate coronary revascularization can be accomplished if myocardial perfusion is quantified by positron emission tomography prior to treatment decision
(
- Contribution to journal › Article
- 2020
-
Mark
Qualitative assessments of myocardial ischemia by cardiac MRI and coronary stenosis by invasive coronary angiography in relation to quantitative perfusion by positron emission tomography in patients with known or suspected stable coronary artery disease
(
- Contribution to journal › Article
-
Mark
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque
(
- Contribution to journal › Article
-
Mark
Survival of Patients With Angina Pectoris Undergoing Percutaneous Coronary Intervention With Intracoronary Pressure Wire Guidance
(
- Contribution to journal › Article
- 2018
-
Mark
Reclassification of Treatment Strategy With Instantaneous Wave-Free Ratio and Fractional Flow Reserve : A Substudy From the iFR-SWEDEHEART Trial
(
- Contribution to journal › Article
- 2016
-
Mark
Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease : Anatomy, Physiology, or Morphology?
(
- Contribution to journal › Scientific review
- 2012
-
Mark
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients: Results From the FEATHER Trial.
(
- Contribution to journal › Article
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article